Market Research Logo

BioSeeker Group AB

BioSeeker Group is a business and competitive intelligence company for investment, venture and R&D management of biotechnology and pharmaceutical companies. It serves the needs of individuals, companies, and institutional clients with a diverse range of information and analysis services.

BioSeeker Group has a strong client focus providing decision-makers, investors, and management people with candid, credible research coverage on biotechnology and pharmaceutical companies. The firm is committed to creating value for clients by providing wisdom and high quality services that meet clients' needs. BioSeeker's clients and projects are kept confidential.

...Show More ...Show Less

222 Reports from BioSeeker Group AB

   
  • p53 Signaling Pathway in Cancer Drug Pipeline Update

    ... activator of p53-regulated genes. This results in three major outputs; cell cycle arrest, cellular senescence or apoptosis. Other p53-regulated gene functions communicate with adjacent cells, repair the damaged DNA or set up positive and negative ... Read More

  • Targeting Metabolic Pathways in Cancer Drug Pipeline Update

    ... and the accumulated number of ceased drugs over the last years amount to another 92 drugs. Targeting Metabolic Pathways In Cancer Drug Pipeline Update lists all drugs and gives you a progress analysis on each ... Read More

  • ErbB Signaling Pathway in Cancer Drug Pipeline Update

    ... cell motility, and survival. Ligand binding to the four closely related members of this RTK family -epidermal growth factor receptor (EGFR, also known as ErbB-1 or HER1), ErbB-2 (HER2), ErbB-3 (HER3), and ErbB-4 (HER4)-induces the ... Read More

  • Transcriptional Misregulation in Cancer Drug Pipeline Update

    ... the accumulated number of ceased drugs over the last years amount to another 204 drugs. Transcriptional Misregulation In Cancer Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of ... Read More

  • The Latest Sales Figures in Oncology Drug Pipeline Update

    ... companies to progressive biotech companies. The analysis leverages the power of BioSeeker's 1stOncology intelligence which combines company disclosed product sales and detailed drug development information. The results is not only a unique insight into the ... Read More

  • Fierce 15 in Oncology Drug Pipeline Update

    ... award are aiming at breakthroughs and big things, not at being 'me-too'. This unique product, the 'Fierce 15 in Oncology Drug Pipeline Update' gathers the last six years (2010-2015) of Fierce 15 awards and identifies ... Read More

  • TCR/CAR-T Therapies in Oncology Drug Pipeline Update

    ... able to launch the first successful CAR-T therapy drug. BioSeeker’s TCR/CAR-T Therapies in Oncology Drug Pipeline Update is the most up to date and comprehensive commercial pipeline review and competitive assessment available on this hot ... Read More

  • HIF-1 Signaling Pathway in Cancer Drug Pipeline Update

    ... and nutrient availability. The hypoxia-inducible factors (HIFs) are a common link between adaptation to low O(2), changes in cancer metabolism, and malignant progression. This report focusses around the cancer drugs targeting the hypoxia-inducible factor 1 ... Read More

  • Conjugated Drugs in Oncology Drug Pipeline Update

    ... the clinical application of ADCs is accelerating rapidly. But antibodies are not the only kind of compound one could conjugate small molecules to, nor the only class of compounds which one can yield targeted therapy ... Read More

  • MicroRNAs in Cancer Drug Pipeline Update

    ... minimal toxicities either as a monotherapy or perhaps even more likely in a combinatorial drug setting. miRNA may also hold great potential as biomarkers, albeit a lot of work is a head of us and ... Read More

  • Colorectal Cancer Drug Pipeline Update

    ... Erbitux heralded a new era in the disease management, and the emergence of other molecular targeted agents should further push survival to an unprecedented level in the coming years. There are today 426 companies plus ... Read More

  • TGF-Beta Receptor Signaling Pathway in Oncology Drug Pipeline Update

    ... 1845 developmental projects in cancer. In addition, there are 2 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 265 drugs. Tgf-Beta Receptor Signaling Pathway In Oncology Drug ... Read More

  • TNF-Alpha Signaling Pathway in Oncology Drug Pipeline Update

    ... 2597 developmental projects in cancer. In addition, there are 5 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 313 drugs. Tnf-Alpha Signaling Pathway In Oncology Drug Pipeline ... Read More

  • Alpha6 Beta4 Integrin Signaling Pathway in Oncology Drug Pipeline Update

    ... Alpha6Beta4 integrin pathway targeting drugs in 1796 developmental projects in cancer. In addition, there is 1 suspended drug and the accumulated number of ceased drugs over the last years amount to another 209 drugs. Alpha6 ... Read More

  • ID Signaling Pathway in Oncology Drug Pipeline Update

    ... family members inhibiting their DNA binding capacity. This family of proteins is comprised of IDs 1, 2, 3 and 4. There are today 117 companies plus partners developing 114 ID pathway targeting drugs in 493 ... Read More

  • Notch Signaling Pathway in Oncology Drug Pipeline Update

    ... today 335 companies plus partners developing 416 Notch pathway targeting drugs in 1497 developmental projects in cancer. In addition, there are 4 suspended drugs and the accumulated number of ceased drugs over the last years ... Read More

  • Androgen Receptor Signaling Pathway in Oncology Drug Pipeline Update

    ... projects in cancer. In addition, there are 2 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 258 drugs. Androgen Receptor Signaling Pathway In Oncology Drug Pipeline Update ... Read More

  • T Cell Receptor Signaling Pathway in Oncology Drug Pipeline Update

    ... receptor signaling. There are today 355 companies plus partners developing 469 T cell receptor pathway targeting drugs in 1756 developmental projects in cancer. In addition, there are 7 suspended drugs and the accumulated number of ... Read More

  • IL-2 Signaling Pathway in Oncology Drug Pipeline Update

    ... in 1619 developmental projects in cancer. In addition, there are 6 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 183 drugs. Il-2 Signaling Pathway In Oncology Drug ... Read More

  • IL-5 Signaling Pathway in Oncology Drug Pipeline Update

    ... developmental projects in cancer. In addition, there are 2 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 86 drugs. Il-5 Signaling Pathway In Oncology Drug Pipeline Update ... Read More

  • Fc Epsilon RI Signaling Pathway in Oncology Drug Pipeline Update

    ... the alpha chain of Fc epsilon RI. The activation pathways are regulated both positively and negatively by the interactions of numerous signaling molecules. These mediators and cytokines contribute to inflammatory responses. There are today 182 ... Read More

  • Targeting Focal Adhesion for the Treatment of Cancer Drug Pipeline Update

    ... At the cell-extracellular matrix contact points, specialized structures are formed and termed focal adhesions, where bundles of actin filaments are anchored to transmembrane receptors of the integrin family through a multi-molecular complex of junctional plaque ... Read More

  • Gap Junctions in Oncology Drug Pipeline Update

    ... each containing six connexins, contributed by each neighboring cell. These channels permit the direct transfer of small molecules including ions, amino acids, nucleotides, second messengers and other metabolites between adjacent cells. Gap junctional communication is ... Read More

  • The MAPK Signaling Pathway in Oncology Drug Pipeline Update

    ... are today 343 companies plus partners developing 463 The MAPK signaling pathway targeting drugs in 1699 developmental projects in cancer. In addition, there are 2 suspended drugs and the accumulated number of ceased drugs over ... Read More

  • mTOR Signaling Pathway in Oncology Drug Pipeline Update

    ... hallmarks of cancer such as cell growth and proliferation, angiogenesis, and bioenergetics. Since mTOR acts as a neoplastic switch that is frequently turned on by many mutations found in cancer, inhibition of mTOR may offer ... Read More

1 2 3 4 5 7 9

Research Assistance

Join Alert Me Now!

Sign Up

Find out more on our blog

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook